INDEMNIFICATION AGREEMENTIndemnification Agreement • October 30th, 2020 • Olema Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of ____________ between Olema Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and ______________ (“Indemnitee”).
OLEMA PHARMACEUTICALS, INC. COMMON STOCK SALES AGREEMENTSales Agreement • March 11th, 2024 • Olema Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Olema Pharmaceuticals, Inc. (the “Company”), confirms its agreement (this “Agreement”) with Oppenheimer & Co. Inc. (the “Agent”), as follows:
Underwriting Agreement Olema Pharmaceuticals, Inc. [·] Shares of Common StockUnderwriting Agreement • November 16th, 2020 • Olema Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Olema Pharmaceuticals, Inc., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [·], 20__ Debt SecuritiesOlema Pharmaceuticals, Inc. • March 1st, 2022 • Pharmaceutical preparations • New York
INDENTURE, dated as of [·], 20__, among Olema Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and[TRUSTEE], as trustee (the “Trustee”):
LOAN AND SECURITY AGREEMENTLoan and Security Agreement • September 5th, 2023 • Olema Pharmaceuticals, Inc. • Pharmaceutical preparations
THIS LOAN AND SECURITY AGREEMENT (this “Agreement”) is dated as of the Effective Date between SILICON VALLEY BANK, a division of First-Citizens Bank & Trust Company (“Bank”) and OLEMA PHARMACEUTICALS, INC., a Delaware corporation (“Borrower”). The parties agree as follows. The parties agree as follows:
November 13, 2020Olema Pharmaceuticals, Inc. • November 16th, 2020 • Pharmaceutical preparations
As you know, you are currently employed by Olema Pharmaceuticals, Inc. (the “Company”) as its Chief Development Officer, pursuant to the terms of an offer letter from the Company dated June 15, 2020 (the “Offer Letter”). In connection with your continuing employment, you and the Company are hereby agreeing to the amended terms of employment set forth herein. The terms set forth in this offer letter (“Agreement”) amend, restate, supersede and replace the terms set forth in the Offer Letter in their entirety.
Olema Pharmaceuticals, Inc.Employee Arbitration Agreement • September 21st, 2020 • Olema Pharmaceuticals, Inc. • Pharmaceutical preparations • California
You are currently employed by Olema Pharmaceuticals, Inc. (the “Company”) as its Chief Scientific Officer. The terms and conditions in this letter (the “Agreement”) will become effective as of the date above, and will supersede and replace the terms and conditions set forth in your offer letter from the Company dated March 20, 2007 (the “Original Offer Letter”).
OLEMA PHARMACEUTICALS, INC. AND _____________, AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF __________Warrant Agreement • March 1st, 2022 • Olema Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between OLEMA PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of [•] and having a corporate trust office in [•], as warrant agent (the “Warrant Agent”).
Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. AMENDED AND RESTATED CLINICAL COLLABORATION AND SUPPLY...Clinical Collaboration and Supply Agreement • May 9th, 2023 • Olema Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This AMENDED AND RESTATED CLINICAL COLLABORATION AND SUPPLY AGREEMENT (the “Agreement”) is made and entered into effective as of January 13, 2022 (the “Effective Date”) by and between Olema Pharmaceuticals, Inc., a Delaware corporation, having a place of business at 665 3rd St, San Francisco, CA 94107 (“Olema”), and Novartis Institutes for BioMedical Research, Inc., a Delaware corporation, having a place of business at 181 Massachusetts Avenue, Cambridge, MA 02139 (“Novartis”). Olema and Novartis are sometimes individually referred to in this Agreement as a “Party” and collectively as the “Parties.”
September 1, 2020 Mr. Sean Bohen VIA EMAIL Re: Offer of Employment Dear Sean:Olema Pharmaceuticals, Inc. • September 21st, 2020 • Pharmaceutical preparations
Olema Pharmaceuticals, Inc. (the “Company”) is pleased to offer you employment as the Company’s Chief Executive Officer (“CEO”) on the terms and conditions set forth in this letter agreement (the “Agreement”).
Olema Pharmaceuticals, inc. 150,000,000 SHARES COMMON STOCK SALES AGREEMENTOlema Pharmaceuticals, Inc. • January 5th, 2024 • Pharmaceutical preparations • New York
Olema Pharmaceuticals, Inc. (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“TD Cowen”), as follows:
Amendment No. 2 to Amended and Restated Clinical Collaboration and Supply AgreementCollaboration and Supply Agreement • May 8th, 2024 • Olema Pharmaceuticals, Inc. • Pharmaceutical preparations
Reference is hereby made to the Clinical Collaboration and Supply Agreement, dated July 22, 2020, as amended via the Amended and Restated Clinical Collaboration and Supply Agreement, dated January 13, 2022, and the Amendment No. 1 to Amended and Restated Clinical Collaboration and Supply Agreement, dated October 5, 2023 (collectively the “Agreement”), by and between Olema Pharmaceuticals, Inc., a Delaware corporation, having a place of business at 780 Brannan Street, San Francisco, CA 94103 (“Olema”), and Novartis Institutes for BioMedical Research, Inc., a Delaware corporation, having a place of business at 181 Massachusetts Avenue, Cambridge, MA 02139 (“Novartis”).
OLEMA PHARMACEUTICALS, INC. AND _____________, AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF __________Debt Securities Warrant Agreement • March 1st, 2022 • Olema Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between OLEMA PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of [•] and having a corporate trust office in [•], as warrant agent (the “Warrant Agent”).
OLEMA PHARMACEUTICALS, INC. STOCK PURCHASE AGREEMENTStock Purchase Agreement • September 5th, 2023 • Olema Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This Stock Purchase Agreement (the “Agreement”) is made as of September 5, 2023 (the “Effective Date”), by and among Olema Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the purchasers whose names and addresses are set forth on the signature pages hereof (each, a “Purchaser” and, collectively, the “Purchasers”).
March 8, 2023 Kinney Horn VIA EMAIL Dear Kinney:Olema Pharmaceuticals, Inc. • May 9th, 2023 • Pharmaceutical preparations
This letter sets forth the substance of the separation and consulting agreement (the “Agreement”) that Olema Pharmaceuticals, Inc. (the “Company”) is offering to you to aid in your employment transition.
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • October 30th, 2020 • Olema Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of September 30, 2020 by and among Olema Pharmaceuticals, Inc., a Delaware corporation (the “Company”), each of the investors listed on Schedule A hereto (the “Series C Investors”), each holder of the Company’s Series A Preferred Stock, $0.0001 par value per share (“Series A Preferred Stock”), each holder of the Company’s Series A-1 Preferred Stock, $0.0001 par value per share (“Series A-1 Preferred Stock”) and each holder of the Company’s Series B Preferred Stock, $0.0001 par value per share (the “Series B Preferred Stock”), listed on Schedule B (the “Prior Investors” and together with the Series C Investors, the “Investors”) and each of the stockholders listed on Schedule C hereto, each of whom is referred to herein as a “Key Holder”.
March 21, 2023 Cyrus Harmon VIA EMAIL Dear Cyrus:Olema Pharmaceuticals, Inc. • May 9th, 2023 • Pharmaceutical preparations
This letter sets forth the substance of the separation agreement (the “Agreement”) that Olema Pharmaceuticals, Inc. (the “Company”) is offering to you to aid in your employment transition.
Re:Employment TermsOlema Pharmaceuticals, Inc. • February 28th, 2022 • Pharmaceutical preparations
Olema Pharmaceuticals, Inc. (the “Company”) is pleased to offer you employment as its Chief Medical Officer, pursuant to the terms of this offer letter agreement (the “Agreement”).
OLEMA PHARMACEUTICALS, INC. AND _____________, AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF __________Common Stock Warrant Agreement • March 1st, 2022 • Olema Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between OLEMA PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of [•] and having a corporate trust office in [•], as warrant agent (the “Warrant Agent”).
DocuSign Envelope ID: DCF0D6AC-6E2F-4DD0-AB52-5A3A0B54EBBF CONSULTING AGREEMENT Effective Date: April 5, 2021 This Consulting Agreement (the “Agreement”) is made as of the Effective Date set forth above by and between Olema Pharmaceuticals, Inc....Consulting Agreement • May 11th, 2021 • Olema Pharmaceuticals, Inc. • Pharmaceutical preparations • California
November 13, 2020Olema Pharmaceuticals, Inc. • November 16th, 2020 • Pharmaceutical preparations
As you know, you are currently employed by Olema Pharmaceuticals, Inc. (the “Company”) as its Chief Executive Officer, pursuant to the terms of an offer letter from the Company dated September 1, 2020 (the “Offer Letter”). In connection with your continuing employment, you and the Company are hereby agreeing to the amended terms of employment set forth herein. The terms set forth in this offer letter (“Agreement”) amend, restate, supersede and replace the terms set forth in the Offer Letter in their entirety.
VIA EMAILNovember • November 16th, 2020 • Olema Pharmaceuticals, Inc. • Pharmaceutical preparations
As you know, you are currently employed by Olema Pharmaceuticals, Inc. (the “Company”) as its Executive Vice President, Chief Legal Officer and Corporate Secretary, pursuant to the terms of an offer letter from the Company dated September 7, 2020 (the “Offer Letter”). In connection with your continuing employment, you and the Company are hereby agreeing to the amended terms of employment set forth herein. The terms set forth in this offer letter (“Agreement”) amend, restate, supersede and replace the terms set forth in the Offer Letter in their entirety.
Amendment No. 1 to Amended and Restated Clinical Collaboration and Supply AgreementCollaboration and Supply Agreement • October 10th, 2023 • Olema Pharmaceuticals, Inc. • Pharmaceutical preparations
Reference is hereby made to the Clinical Collaboration and Supply Agreement, dated July 22, 2020, as amended via the Amended and Restated Clinical Collaboration and Supply Agreement, dated January 13, 2022 (collectively the “Agreement”), by and between Olema Pharmaceuticals, Inc., a Delaware corporation, having a place of business at 780 Brannan Street, San Francisco, CA 94103 (“Olema”), and Novartis Institutes for BioMedical Research, Inc., a Delaware corporation, having a place of business at 181 Massachusetts Avenue, Cambridge, MA 02139 (“Novartis”).
